APA Цитирование

Enjoji, M., Machida, K., Kohjima, M., Kato, M., Kotoh, K., Matsunaga, K., . . . Nakamuta, M. (2010). NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. BioMed Central.

Chicago-стиль цитирования

Enjoji, Munechika, Kazuyuki Machida, Motoyuki Kohjima, Masaki Kato, Kazuhiro Kotoh, Kazuhisa Matsunaga, Manabu Nakashima, and Makoto Nakamuta. NPC1L1 Inhibitor Ezetimibe Is a Reliable Therapeutic Agent for Non-obese Patients With Nonalcoholic Fatty Liver Disease. BioMed Central, 2010.

MLA-цитирование

Enjoji, Munechika, et al. NPC1L1 Inhibitor Ezetimibe Is a Reliable Therapeutic Agent for Non-obese Patients With Nonalcoholic Fatty Liver Disease. BioMed Central, 2010.

Предупреждение: эти цитированмия не могут быть всегда правильны на 100%.